Eli Lilly seals $1bn genetics deal
17-12-2020
SCOTUS refuses to hear Eli Lilly patent win
16-06-2020
Eli Lilly secures exclusive rights to chronic pain treatment
03-06-2019
Jonathan Weiss / Shutterstock.com
Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Dermira, merger, glycopyrronium, lebrikizumab, blockbuster
